HOME >> BIOLOGY >> NEWS
Researchers find a genetic connection in Sudden Infant Death Syndrome (SIDS)

d.

The results suggest an association between SIDS and the 5-HTT gene. "There was a significant difference in genotype distribution and an increased frequency of the L allele in SIDS cases versus ethnicity/gender matched controls with no family history of SIDS or autonomic dysfunction," the authors report. "Furthermore, there were significantly fewer SIDS cases versus controls with no long allele (S/S genotype) in the entire cohort and within the Caucasian subgroup; and significantly more SIDS cases versus controls with no short allele (L/L genotype) in the entire cohort."

The researchers also found that genotype frequency distributions and allele frequency distributions for 5-HTT were significantly different when evaluated across all ethnic groups. Despite ethnic variations, however, SIDS cases were more likely than controls to have the long allele in the Japanese, Caucasian, and African American study samples.

The study's results are compelling, though limited by the research design that included only confirmed anonymous SIDS cases from the NIH-supported University of Maryland Brain Bank, according to Dr. Weese-Mayer. Further studies should encompass larger numbers and more ethnicities and also include the 5-HTT intron 2 VTNR which influences gene expression. Likewise, Dr. Weese-Mayer et al pointed out that "recognizing the strong relationship between tobacco exposure (prenatal and postnatal) and SIDS risk, future studies of genetic polymorphisms must also include detailed smoking history to clarify the role of gene-environment interaction."

"If a larger data set reflects observations similar to those in this report," the authors conclude, "the serotonergic system will represent a key area for further investigation into the causal basis for SIDS, with the goal of identifying genetic risk factors that will aide in recognizing at-risk individuals who require specialized intervention strategies and in counseling families as to the risk of
'"/>

Contact: John M. Pontarelli
jpontare@rush.edu
312-942-5949
Rush University Medical Center
17-Jan-2003


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: